Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5018743 | 0.85 | PTGS1 (0.55) | ALDH1A1PPARGPPARDPPARARAB9A | |
| SCHEMBL28944932 | 0.85 | TAAR1 (0.56) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| SCHEMBL16728148 | 0.84 | SLC7A5 (0.55) | ALDH1A1PPARGPPARDPPARARAB9A | |
| Amphetamine SCHEMBL21464672 | 0.84 | TAAR1 (0.70) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL29185448 | 0.84 | TAAR1 (0.70) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| SCHEMBL251733 | 0.83 | ANPEP (0.62) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| SCHEMBL5183224 | 0.83 | ANPEP (0.62) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| SCHEMBL2439514 | 0.83 | ANPEP (0.62) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| SCHEMBL288025 | 0.82 | SLC7A5 (0.72) | SLC6A3ALDH1A1 | |
| SCHEMBL44097 | 0.82 | SLC7A5 (0.72) | SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | Pharmapotheca A, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | Pharmapotheca A Inc. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | CHEMAPOTHECA, LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | Pharmapotheca A, Inc. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11123310-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | PHARMAPOTHECA, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210030699-A1 | Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms | PHARMAPOTHECA, LLC (US) | 2021-02-04 | — | — | US | disclosed |
| US-20200352883-A1 | METHODS OF TREATMENT USING AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC (US) | 2020-11-12 | — | — | US | disclosed |
| US-20180243241-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC | 2018-08-30 | — | — | US | disclosed |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120321591-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LIMITED | 2012-12-20 | — | — | US | disclosed |
| US-8293714-B2 | Anti-angiogenic compounds | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2012-10-23 | — | — | US | disclosed |
| US-20100003267-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LIMITED | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11123310-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | TAAR1 52/4885SLC6A2 3/4885SLC6A4 6/4885 |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | SLC6A3, SLC6A2, CES2 | TAAR1 51/4885SLC6A2 2/4885SLC6A4 4/4885 |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | TAAR1 4174/4885SLC6A2 3436/4885SLC6A4 3408/4885 |
| US-20100003267-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, FLT1 | TAAR1 4758/4885SLC6A2 3685/4885SLC6A4 3719/4885 |
| US-20200352883-A1 | METHODS OF TREATMENT USING AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | SLC6A3, SLC6A2, CES2 | TAAR1 40/4885SLC6A2 2/4885SLC6A4 4/4885 |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | TAAR1 37/4885SLC6A2 3/4885SLC6A4 6/4885 |
| US-20210030699-A1 | Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms | SLC6A3, SLC6A2, CES2 | TAAR1 51/4885SLC6A2 2/4885SLC6A4 4/4885 |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | TAAR1 37/4885SLC6A2 3/4885SLC6A4 6/4885 |
| US-20120321591-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, FLT1 | TAAR1 4784/4885SLC6A2 4072/4885SLC6A4 4203/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | TAAR1 4189/4885SLC6A2 3422/4885SLC6A4 3371/4885 |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | TAAR1 52/4885SLC6A2 3/4885SLC6A4 6/4885 |
| US-20180243241-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | SLC6A3, CES2, SLC6A2 | TAAR1 52/4885SLC6A2 3/4885SLC6A4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.